News
Hosted on MSN29d
FDA approves label updates for BMS’ CAR T cell therapiesB ristol Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has given approval to label updates for its CAR T cell therapies, Breyanzi (lisocabtagene maraleucel; liso ...
Hosted on MSN3mon
Amgen got expanded FDA label approval for Uplizna - MSNAmgen (NASDAQ: NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label approval for Uplizna, now approved as a treatment for immunoglobulin G4-related ...
The Food and Drug Administration (FDA) has approved an updated label for both chimeric antigen receptor (CAR) T-cell therapies, Breyanzi ® (lisocabtagene maraleucel) and Abecma ® (idecabtagene ...
Bristol Myers (BMY) receives FDA approval for label updates for Breyanzi and Abecma, that can ease access to the cancer cell therapies. Read more here.
Amgen (NASDAQ: NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label approval for Uplizna, now approved as a treatment for immunoglobulin G4-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback